Ra Capital Management, L.P. Orchard Therapeutics PLC Transaction History

Ra Capital Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.42 - $0.78 $2.79 Million - $5.19 Million	-6,653,904 Reduced 68.63%	3,040,885 $1.78 Million
Q4 2021 Feb 14, 2022	SELL	$1.16 - $2.23 $1.55 Million - $2.97 Million	-1,333,933 Reduced 12.1%	9,694,789 $12.8 Million
Q3 2021 Nov 15, 2021	SELL	$2.24 - $4.29 $2.88 Million - $5.52 Million	-1,286,491 Reduced 10.45%	11,028,722 $25.4 Million
Q3 2020 Nov 16, 2020	BUY	$4.11 - $6.45 $7.86 Million - $12.3 Million	1,912,026 Added 18.38%	12,315,213 $50.6 Million
Q2 2020 Aug 14, 2020	BUY	$5.75 - $11.99 $221,541 - $461,962	38,529 Added 0.37%	10,403,187 $45.7 Million
Q1 2020 May 15, 2020	BUY	$5.65 - $15.71 $22.5 Million - $62.4 Million	3,974,757 Added 62.2%	10,364,658 $57 Million
Q4 2019 Feb 14, 2020	BUY	$10.15 - $15.58 $11.8 Million - $18.2 Million	1,165,426 Added 22.31%	6,389,901 $87.9 Million
Q3 2019 Nov 14, 2019	BUY	$11.88 - $16.72 $1.38 Million - $1.94 Million	116,145 Added 2.27%	5,224,475 $62.1 Million
Q1 2019 May 15, 2019	BUY	$12.01 - $19.49 $3.15 Million - $5.11 Million	262,397 Added 5.41%	5,108,330 $91.3 Million
Q4 2018 Feb 14, 2019	BUY	$12.4 - $18.7 $60.1 Million - $90.6 Million	4,845,933 New	4,845,933 $76.2 Million

545K

Ticker ORTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,458,000
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.